(Source: Novartis AG) The median Duration of Response for BRAF V600E-mutant NSCLC patients treated with Tafinlar + Mekinist combination therapy was 9 months Efficacy analyses also presented for INC280 (capmatinib) in cMET+ NSCLC Novartis' growing commitment in treating NSCLC supported by data for three distinct targeted therapies Basel, June 6, 2016- Novartis today announced new data for multiple investigational and established non-small cell lung cancer (NSCLC) treatments, including results from a pivotal, Phase II study of Tafinlar (dabrafenib) in combination with Mekinist (trametinib) in patients with BRAF V600E-mutation positive (BRAF V600E+) NSCLC. In the study, patients treated with...
↧